8-K: NewAmsterdam Pharma Reports Positive Alzheimer's Biomarker Data from Pivotal BROADWAY Trial, Highlighting Obicetrapib's Potential Beyond Cardiovascular Disease

NewAmsterdam Pharma announced positive topline data from its Phase 3 BROADWAY clinical trial, demonstrating that obicetrapib significantly reduced Alzheimer's disease biomarkers, particularly in ApoE4 carriers.

Summary

• NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) released positive topline data from prespecified Alzheimer's Disease (AD) biomarker analyses within its pivotal Phase 3 BROADWAY clinical trial.
• The AD sub-study assessed the effect of obicetrapib on plasma biomarkers of AD in 1,727 patients, including 367 ApoE4 carriers, over 12 months.
• Obicetrapib treatment led to statistically significant lower absolute changes in p-tau217 compared to placebo over 12 months in both the full ITT population (p<0.002) and in ApoE4 carriers (p=0.0215).
• This data supports an emerging link between CETP-inhibition and the prevention of AD pathology, suggesting a potential preventive strategy for Alzheimer's disease.
• The BROADWAY trial was primarily designed to evaluate obicetrapib's low-density lipoprotein cholesterol (LDL-C) lowering efficacy, previously showing a 33% reduction in LDL-C after 84 days.
• Obicetrapib is an oral, low-dose CETP inhibitor being developed for patients at risk of cardiovascular disease (CVD) with elevated LDL-C, and has shown a side effect profile similar to placebo in multiple trials.

Sentiment

Score: 9

Explanation: The announcement is highly positive, reporting statistically significant results for a novel indication (Alzheimer's disease prevention) for an existing drug candidate. This expands the potential market and therapeutic scope of obicetrapib significantly, beyond its primary cardiovascular indication. The results are clear, robust (statistically significant), and address a major unmet medical need.

Positives

• Obicetrapib demonstrated statistically significant reductions in p-tau217, a key Alzheimer's disease biomarker, in both the overall study population (p<0.002) and in high-risk ApoE4 carriers (p=0.0215).
• These findings suggest a potential for obicetrapib to serve as a preventive strategy for Alzheimer's disease, especially for the over 25% of the population carrying ApoE4 risk alleles who currently lack FDA-approved prevention options.
• The results build upon existing genetic, Mendelian randomization, and preclinical data, strengthening the evidence for CETP inhibition's role in mitigating AD progression.
• Obicetrapib has an established safety profile across multiple large clinical trials, with a side effect profile similar to placebo, which could facilitate clinical implementation.
• The drug's oral, once-daily administration offers convenience for patients.
• The data further differentiates obicetrapib, enhancing its profile as a therapy with potential benefits across cardiometabolic disease and neurodegeneration, in addition to its significant cardiovascular benefits.

Risks

• Actual events and circumstances may differ materially from assumptions and predictions due to various factors beyond the company's control.
• Changes in domestic and foreign business, market, financial, political, and legal conditions could impact results.
• Risks related to the approval of the product candidate and the timing of expected regulatory and business milestones, including potential commercialization, exist.
• Topline, initial, or preliminary results from clinical trials may not be predictive of final results, and early clinical trial results may not be indicative of later trials or actual clinical use.
• There is potential for varying interpretations of the AD sub-study results.
• The company's ability to negotiate definitive contractual arrangements with potential customers is uncertain.
• The impact of competitive product candidates could affect the company's business.
• Ability to obtain sufficient supply of materials is a risk.
• Global economic and political conditions, including the Russia-Ukraine and Israel-Hamas conflicts, could have an impact.
• Uncertainty regarding outcomes of ongoing clinical trials, particularly as they relate to regulatory review and potential approval for the product candidate.
• Risks are associated with the company's efforts to commercialize a product candidate.
• The company's ability to negotiate and enter into definitive agreements on favorable terms, if at all, is not guaranteed.
• Intellectual property related claims could arise.
• The company's ability to attract and retain qualified personnel is crucial.
• Ability to continue to source the raw materials for the product candidate is a factor.

Future Outlook

The company plans to present the full results from the AD sub-study analysis in a Developing Topics oral presentation at the Alzheimer's Association International Conference in Toronto at the end of July 2025. The positive data further strengthens obicetrapib's profile as a uniquely differentiated therapy with the potential to address multiple interrelated drivers of chronic cardiometabolic disease and neurodegeneration, supporting a potential preventive strategy for Alzheimer's disease.

Management Comments

• Michael Davidson, M.D., Chief Executive Officer: "These findings strongly support a potential preventive strategy for Alzheimers disease. In this study obicetrapib, a potent CETP inhibitor, improved the progression of key plasma biomarkers of AD pathology over a 12-month period in patients with ASCVD. These data further differentiate obicetrapib and underscore the critical role CETP inhibition may have in mitigating the risk of AD progression, alongside the significant cardiovascular benefits obicetrapib has shown in our pivotal Phase 3 trials."
• Philip Scheltens, professor emeritus at Amsterdam University Medical Center: "The ability to reduce pathological biomarker progression suggests a potential to alter disease trajectory in this population, thereby delaying or preventing the onset of symptoms. The established safety profile of obicetrapib, demonstrated across multiple large clinical trials, combined with its oral administration, may greatly facilitate clinical implementation."
• John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer: "The data shared today support our belief that CETP inhibition and specifically raising small functional HDL particles offers a novel and targeted approach to reducing that risk. When viewed alongside the totality of evidence generated to date, including improvements in LDL-C, small LDL particles, Lipoprotein (a), and key biomarkers associated with diabetes and renal function, these novel data on the prevention of AD-associated pathology further strengthen obicetrapibs profile as a uniquely differentiated therapy with the potential to address multiple interrelated drivers of chronic cardiometabolic disease and neurodegeneration."

Industry Context

This announcement positions NewAmsterdam Pharma at the intersection of cardiovascular disease and neurodegenerative disorders, specifically Alzheimer's disease. The positive AD biomarker data for obicetrapib, a CETP inhibitor primarily known for LDL-C lowering, suggests a novel therapeutic pathway for AD prevention, particularly for ApoE4 carriers who currently lack approved options. This could open up a significant new market opportunity for the company beyond its core cardiovascular focus, differentiating it from competitors solely focused on lipid management or traditional AD drug development.

Comparison to Industry Standards

• The document highlights that for ApoE4 carriers, who represent over 25% of the population and are at greater risk for AD, there are currently no FDA-approved prevention options, positioning obicetrapib as a potential first-in-class preventive therapy.
• While the document does not name specific comparable companies or projects for AD prevention, it implicitly contrasts obicetrapib's approach (CETP inhibition and HDL particle raising) with existing or failed AD therapies that often target amyloid or tau directly.
• The established safety profile of obicetrapib across multiple large clinical trials, combined with its oral administration, is presented as a significant advantage compared to other investigational or approved therapies that may have more complex administration routes or less favorable safety profiles.

Stakeholder Impact

• **Shareholders**: Highly positive impact due to the significant expansion of obicetrapib's potential market and therapeutic value, potentially leading to increased valuation and future revenue streams.
• **Patients (with ASCVD/HeFH)**: Continued positive outlook for a safe and effective LDL-C lowering therapy.
• **Patients (at risk of AD, especially ApoE4 carriers)**: Significant positive impact as obicetrapib could offer a novel, oral, and well-tolerated preventive option for Alzheimer's disease, a condition with limited current prevention strategies.
• **Healthcare Providers**: Potential new tool for managing both cardiovascular risk and Alzheimer's disease risk, particularly in high-risk populations.
• **Regulatory Authorities**: The positive biomarker data could pave the way for future regulatory discussions regarding AD prevention claims for obicetrapib.

Next Steps

• NewAmsterdam Pharma plans to present the full results from the AD sub-study analysis in a Developing Topics oral presentation at the Alzheimer's Association International Conference (AAIC) in Toronto at the end of July 2025.

Key Dates

Recommendation

Keywords

NewAmsterdam Pharma, NAMS, Obicetrapib, Alzheimer's Disease, AD, BROADWAY trial, Phase 3 clinical trial, Biomarker, p-tau217, ApoE4, CETP inhibitor, Cardiovascular Disease, LDL-C, Clinical data, Biopharmaceutical, Neurodegeneration